The Merged RDEC Scheme and ERIS Under CTA 2009 Part 13 and Finance Act 2024: The 20% Above-the-Line Credit, 30% R&D Intensity Threshold, Contracted-Out R&D, Overseas Restrictions, PAYE/NIC Cap, and HMRC Compliance
Finance Act 2024 Schedule 1 permanently rewrote United Kingdom R&D tax relief under CTA 2009 Part 13 for accounting periods beginning on or after 1 April 2024. Corporate tax managers, finance directors, and R&D advisers must now navigate a unified Merged RDEC Scheme (20% taxable above-the-line credit under s. 1042G/s. 1042H, 15.00% net at 25% CT, or 16.20% cash for loss-making and small-profits claimants under the 19% Step 2 rate in s. 1042K(5)), alongside Enhanced R&D Intensive Support (ERIS) for loss-making SMEs clearing the 30% R&D intensity threshold (86% additional deduction + 14.5% payable credit = 26.97% net cash).
Three complete, reconciled UK companies carry every statutory computation from trial balance to CT600L and IAS 20 / FRS 102 financial statements: Northbridge Photonics Ltd (£2,900,000 qualifying R&D, £580,000 gross RDEC, £435,000 net benefit in full-profit Scenario A1 vs. £435,000 Step 7 cash + £50,000 Step 2 carry-forward in Scenario A2 on a -£200,000 pre-RDEC loss), Fenland BioCompute Ltd (34.00% R&D intensity comparing £229,245 ERIS cash against £137,700 Merged RDEC cash, plus Year 2 grace period sensitivity saving £82,929), and Clyde Robotics Systems Ltd (failing the IP exemption at 19.05% connected EPWs, triggering the £110,000 PAYE/NIC cap, deferring £26,080 at Step 3 under s. 1042J, and excluding £180,000 Polish firmware under s. 1138A and £220,000 customer-contemplated work under s. 1133).
What is inside:
15 chapters in four parts covering CTA 2009 Part 13 (Chapter 1A Merged RDEC and Chapter 2 ERIS), Finance Act 2024 Schedule 1, and the March 2023 DSIT Guidelines
Complete seven-step discharge mechanics (CTA 2009 s. 1042I, s. 1042K(2) & (5), s. 1042L, s. 1042J(2), and s. 1042K(9)), distinguishing Step 2 notional tax carry-forwards from Step 3 PAYE/NIC cap carry-forwards
ERIS 30% intensity ratio (s. 1045ZA), pre-R&D loss gate (s. 1044(2A)), 1-year grace period, abolition of subsidised expenditure restrictions across both regimes, and NPV breakeven analysis
New contracted-out R&D decision-maker / contemplated rule (s. 1133, s. 1042F & s. 1053A irrelievable-client carve-outs) and section 1138A overseas expenditure restrictions
PAYE/NIC cap (£20,000 + 300% PAYE/NIC) and the two-limb IP creation + <= 15% connected-party exemption (s. 1112E)
Computes the 7-step Merged RDEC waterfall (exact s. 1042K(2) & (5)), ERIS 30% intensity test and pre-R&D loss gate, section 1138A overseas and section 1133 contracted-out filters, PAYE/NIC cap and 15% IP exemption cliff, and IAS 20 reconciliation. Pre-loaded with Northbridge, Fenland, and Clyde, 100% live formulas, zero macros, zero locked cells (18 KB).
United Kingdom tax legislation is stated as of November 2026, reflecting CTA 2009 Part 13 as rewritten by Finance Act 2024 Schedule 1 (effective for accounting periods beginning on or after 1 April 2024), the DSIT Guidelines (March 2023), and HMRC CIRD Manual updates. Any future Finance Act revisions will be posted here.
Also by Julian R. Sterling
Related UK corporate tax and international tax handbooks. The full list is on the author page.